PIDD1 and B-cell non-Hodgkin lymphoma: Strikingly, Raidd deficiency also had no influence on tumor latency in c-Myc-driven B-cell lymphomas (Figure 3a), contrasting the findings with Caspase-2- or Pidd1-deficient mice, where Caspase-2 acts as a tumor suppressor and Pidd1 as a tumor promoter in this model.